High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases

Table 1

Patient characteristics (sites of metastasis, disease response, and duration of survival).

Patient	No. of brain lesions at diagnosis of brain metastases	Extracranial sites of metastasis	Intracranial response	Extracranial response	Global response	Duration of survival; from HD IL-2 initiation; (months)	Duration of survival from diagnosis of brain metastases (months)
1	2	Subcutaneous lesions	Undocumented progression	Progression	Progression	6.7	7.4
2	1	None at start of HD IL-2; (small bowel mets s/p resection)	Progression	n/a	Progression	10.6	13.5
3	1	Lungs	n/a; (complete radiosurgical response of solitary brain met)	Partial response; (residual lung lesions resected)	Surgical complete response	19.0	23.7
4	3	Muscles, retrocrural soft tissue	Progression	Stable disease	Progression	13.3	15.2
5	3	Pulmonary soft tissue, LNs, liver, kidney, prostate, and bones	Progression	Mixed response	Progression	18.2	19.6
6	15–20	Lung (multiple), paraspinal muscles	Partial response	Mixed response	Progression	5.3	5.4
7	1	Lung (multiple), mediastinum,; soft tissue, kidney, spleen, LNs, and bones	Undocumented progression	Progression	Progression	2.1	5.1
8	7	Hilum, lungs, pulm. soft tissue, and adrenal glands	Progression	Progression	Progression	3.0	4.7